Invention Grant
- Patent Title: Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists
-
Application No.: US16831135Application Date: 2020-03-26
-
Publication No.: US11312683B2Publication Date: 2022-04-26
- Inventor: Andre Chollet
- Applicant: ObsEva S.A.
- Applicant Address: CH Plan-les-Ouates
- Assignee: ObsEva S.A.
- Current Assignee: ObsEva S.A.
- Current Assignee Address: CH Plan-les-Ouates
- Agency: Clark & Elbing LLP
- Priority: EP13183723 20130910
- Main IPC: C07D207/22
- IPC: C07D207/22 ; C07D207/09 ; A61K9/00 ; A61K31/40
Abstract:
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
Public/Granted literature
- US20210047266A1 PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS Public/Granted day:2021-02-18
Information query
